INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 31, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 620,270 | -- | 620,270 |
| Feb 13, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 568,343 | -- | 500,000 |
| Feb 13, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 568,343 | -- | 568,343 |
| Jun 13, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 500,000 | -- | 500,000 |
| Jun 13, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 500,000 | -- | 253,316 |
| Jul 21, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 500,000 | -- | 500,000 |
| Jul 21, 2016 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Bona fide gift | 500,000 | -- | 67,976 |
| Jun 27, 2012 |
Director, EVP CSO Pres REGN Res Lab
|
Director, EVP CSO Pres REGN Res Lab | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 500,000 | -- | 1,333,041 |
| Dec 17, 2007 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 500,000 | -- | 563,094 |
| Feb 16, 2018 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 400,000 | -- | 86,820 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.